Hangzhou-based biotech start-up MindRank has progressed to Phase 3 clinical trials for its weight-loss drug, making it China’s first artificial intelligence-assisted Category 1 new drug to reach this stage.MindRank announced last month that it had initiated a Phase 3 clinical trial in China for MDR-001, a small molecule GLP-1 receptor agonists designed with the help of AI. GLP-1 receptor agonists mimic natural hormones to regulate blood sugar and appetite.According to Niu Zhangming, MindRank’s...